Study your flashcards anywhere!

Download the official Cram app for free >

  • Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

How to study your flashcards.

Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key

Up/Down arrow keys: Flip the card between the front and back.down keyup key

H key: Show hint (3rd side).h key

A key: Read text to speech.a key

image

Play button

image

Play button

image

Progress

1/21

Click to flip

21 Cards in this Set

  • Front
  • Back
  • 3rd side (hint)
amantadine MOA
"a man to dine" take off his coat. Blocks viral penetration/ uncoating (M2 prot); may buffer pH of endosome. Release of dopamine from intact nerve terminals.
amantadine clinical use
Manatadine blocks influenza A and rubellA and causes problemms with the cerebellA. Tx for parkinsons
amantadine toxicity
ataxia, dizzyness, slurred speech
amantadine mechanism of resistance
mutated M2 prot. 90% flu resistant to amantadine. Rimantadine has less AE's and doesn’t X BBB
zanamivir, oseltamivir MOA
inhibits influenza neuraminidase. Progeny release decreased
zanamivir, oseltamivir clinical use
influenza A, B
ribavirin MOA
inhibits syn of guanine nucleotides by competitively inhibiting IMP dehydrogenase
ribavirin clinical use
RSV, chronic hep C
ribavirin toxicity
hemolytic anemia. Severe teratogen
acyclovir MOA
inhibits viral DNA pol when PHOSPHORYLATED BY VIRAL THYMIDINE KINASE
acyclovir clinical use
HSV, VZV, EBV. Mucocutaneous and genital herpes lesions. Prophylax in immunocompromised patients
acyclovir toxicity
delerium, tremor, nephrotoxicity
acyclovir mech of resistance
lack of thymidine kinase
gancyclovir MOA
phosphorylation by viral kinase. Pref inhibits CMV DNA polymerase
gancyclovir clinical use
CMV, esp in immunocompromised pts.
gancyclovir toxicity
leukopenia, neutropenia, thrombocytopenia, renal tox. More toxic to host enzymes than acyclovir
None
gancyclovir mech of resistance
mutated CMV DNA polymerase or lack of thymidine kinase
foscarnet MOA
viral DNA pol inhibitor tha tbinds pyrophosphate binding site of the enz. DOES NOT REQUIRE ACTIVATION BY VIRAL KINASE
foscarnet flinical use
CMV retinitis in immuno comporomised when gancyclovir fails. Acyclovir resistant HSV
foscarnet tox
nephrotoxicity
foscarnet mechanism of resistance
mutated DNA polymerase